Does a low-toxicity IL-2-based immunocytokine retain antitumor activity despite its high degree of IL-2 receptor selectivity?
The qualities of low toxicity and single-agent efficacy shown suggest that NHS-IL2LT is a good candidate for therapeutic approaches combining standard cytotoxic and immune therapies. In fact, this molecule (also known as Selectikine or EMD 521873) is currently in phase I clinical trial.
We report that tSS is a quantitative index of "target-lesion" PCI complexity, which is easy to measure with good reproducibility. tSS significantly and independently correlates with RD, although the strength of the association is less than for other predictors of RD (gender, diabetes, and BMI). tSS may be used to determine the RD from PCI and enhance patient risk-stratification when formulating a PCI strategy.